Skip to main content

BioNet-Asia Co., Ltd.

BioNet is a Thai-French fully-integrated vaccine company with a manufacturing base in Thailand and with clinical, regulatory and business operations in France, Australia and Thailand. BioNet aims to provide rapid access to life-saving vaccines to the neediest on all continents.

In its state-of-the-art vaccine plant, more than 250 highly-skilled employees develop the vaccines of tomorrow against Zika, Dengue and COVID-19 diseases. BioNet already produces recombinant acellular pertussis vaccines in accordance to Good Manufacturing Practices (GMP) PIC/S standards. Two innovative recombinant acellular pertussis vaccines are licensed in Thailand, Boostagen®, a TdaP vaccine (the combined tetanus toxoid, reduced diphtheria toxoid, recombinant acellular pertussis) and Pertagen®, the world’s only monovalent recombinant pertussis vaccine approved for adolescents and adults, including pregnant women.

Because we believe sharing vaccine expertise can accelerate the global development of innovative vaccines, we keep on building long-term and fruitful collaborations with universities, research institutes, biotech companies and vaccine manufacturers around the world.